Clinical Trial Update: Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

View source ↗

Summary

A completed real-world study assessing high-dose tafamidis for its effect on neurologic disease progression in patients with mixed-phenotype transthyretin amylo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloidosis Cardiomyopathy

Drugs mentioned

• Tafamidis (tafamidis)

Snippet

Sponsor: Pfizer | Conditions: Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) | Status: COMPLETED